Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF

Marianna Adamo,Matteo Pagnesi,Mattia Di Pasquale,Alice Ravera,Kenneth Dickstein,Leong L Ng,Stefan D Anker,John G Cleland,Gerasimos S Filippatos,Chim C Lang,Piotr Ponikowski,Nilesh J Samani,Faiez Zannad,Dirk J van Veldhuisen,Erik Lipsic,Adriaan Voors,Marco Metra

DOI: https://doi.org/10.1016/j.ijcard.2023.131664

2024-03-15

Abstract:Background: Mitral regurgitation (MR) frequently coexists with heart failure (HF). Objectives: To better understand potential pathophysiological differences between patients with HF with or without moderate-severe MR, we compared differentially expressed circulating biomarkers between these two groups. Methods: The Olink Proteomics® Multiplex Cardiovascular (CVD) -II, CVD-III, Immune Response and Oncology-II panels of 363 unique proteins from different pathophysiological domains were used to investigate the biomarker profiles of HF patients from index and validation cohorts of the BIOSTAT-CHF study stratified according to the presence of moderate-to-severe MR or no-mild MR. Results: The index cohort included 888 patients (46%) with moderate-to-severe MR and 1029 (54%) with no-mild MR at baseline. The validation cohort included 522 patients (33%) with moderate-to-severe MR and 1076 (66%) with no-mild MR at baseline. Compared to patients with no-mild MR, those with moderate-to-severe MR had lower body mass index, higher comorbidity burden, signs and symptoms of more severe HF, lower systolic blood pressure, and larger left atrial and ventricular dimensions, in both cohorts. NT-proBNP, CA125, fibroblast growth factor 23 (FGF23) and growth hormone 1 (GH1) were up-regulated, whereas leptin (LEP) was down-regulated in patients with moderate-severe MR versus no-mild MR, in both index and validation cohorts. Conclusion: Circulating biomarkers differently expressed in HF patients with moderate-severe MR versus no-mild MR were related to congestion, lipid and mineral metabolism and oxidative stress. These findings may be of value for the development of novel treatment targets in HF patients with MR.